Loading...

Bonesupport Holding

DB:2B4
Snowflake Description

Flawless balance sheet with exceptional growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2B4
DB
SEK1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes for the treatment of bone voids Sweden and internationally. The last earnings update was 50 days ago. More info.


Add to Portfolio Compare Print
2B4 Share Price and Events
7 Day Returns
7.3%
DB:2B4
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
59.4%
DB:2B4
-9.2%
DE Biotechs
-6.7%
DE Market
2B4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bonesupport Holding (2B4) 7.3% 2.2% 5.7% 59.4% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 2B4 outperformed the Biotechs industry which returned -9.2% over the past year.
  • 2B4 outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

2B4 Value

 Is Bonesupport Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Bonesupport Holding to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Bonesupport Holding.

DB:2B4 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2B4
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 22%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:2B4 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Bonesupport Holding is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:2B4 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -165.20 Analyst x2 -152.95
2020 -99.20 Analyst x2 -85.03
2021 3.20 Analyst x2 2.54
2022 133.00 Analyst x1 97.73
2023 210.20 Analyst x1 143.00
2024 276.58 Est @ 31.58% 174.21
2025 337.92 Est @ 22.18% 197.06
2026 390.60 Est @ 15.59% 210.89
2027 433.50 Est @ 10.98% 216.69
2028 467.12 Est @ 7.76% 216.19
Present value of next 10 years cash flows SEK1,020.32
DB:2B4 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK467.12 × (1 + 0.23%) ÷ (8.01% – 0.23%)
SEK6,017.03
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK6,017.03 ÷ (1 + 8.01%)10
SEK2,784.73
DB:2B4 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK1,020.32 + SEK2,784.73
SEK3,805.05
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK3,805.05 / 51.80
SEK73.46
DB:2B4 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2B4 represents 0.09279x of OM:BONEX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09279x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 73.46 x 0.09279
€6.82
Value per share (EUR) From above. €6.82
Current discount Discount to share price of €2.06
= -1 x (€2.06 - €6.82) / €6.82
69.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Bonesupport Holding is available for.
Intrinsic value
>50%
Share price is €2.06 vs Future cash flow value of €6.82
Current Discount Checks
For Bonesupport Holding to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Bonesupport Holding's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Bonesupport Holding's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bonesupport Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bonesupport Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2B4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-3.46
OM:BONEX Share Price ** OM (2019-04-18) in SEK SEK22.2
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bonesupport Holding.

DB:2B4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BONEX Share Price ÷ EPS (both in SEK)

= 22.2 ÷ -3.46

-6.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bonesupport Holding is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Bonesupport Holding is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Bonesupport Holding's expected growth come at a high price?
Raw Data
DB:2B4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
55.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bonesupport Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bonesupport Holding's assets?
Raw Data
DB:2B4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK5.38
OM:BONEX Share Price * OM (2019-04-18) in SEK SEK22.2
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:2B4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BONEX Share Price ÷ Book Value per Share (both in SEK)

= 22.2 ÷ 5.38

4.13x

* Primary Listing of Bonesupport Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bonesupport Holding is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Bonesupport Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bonesupport Holding has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2B4 Future Performance

 How is Bonesupport Holding expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bonesupport Holding expected to grow at an attractive rate?
  • Bonesupport Holding's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Bonesupport Holding's earnings growth is expected to exceed the Germany market average.
  • Bonesupport Holding's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2B4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2B4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 55.9%
DB:2B4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 41.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2B4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2B4 Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 402 -10 11 1
2020-12-31 322 -95 -79 4
2019-12-31 207 -156 -146 4
DB:2B4 Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 97 -172 -176
2018-09-30 101 -147 -181
2018-06-30 119 -128 -146
2018-03-31 128 -112 -132
2017-12-31 129 -108 -129
2017-09-30 132 -112 -112
2017-06-30 126 -106 -124
2017-03-31 114 -103 -124
2016-12-31 105 -82 -110

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bonesupport Holding's earnings are expected to grow significantly at over 20% yearly.
  • Bonesupport Holding's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2B4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Bonesupport Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2B4 Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.20 0.20 0.20 1.00
2020-12-31 -1.45 -1.30 -1.55 3.00
2019-12-31 -2.73 -2.50 -2.93 3.00
DB:2B4 Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -3.46
2018-09-30 -3.57
2018-06-30 -2.92
2018-03-31 -2.91
2017-12-31 -3.24
2017-09-30 -3.27
2017-06-30 -4.38
2017-03-31 -4.62
2016-12-31 -4.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bonesupport Holding is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Bonesupport Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bonesupport Holding has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2B4 Past Performance

  How has Bonesupport Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bonesupport Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bonesupport Holding does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bonesupport Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bonesupport Holding's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bonesupport Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bonesupport Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2B4 Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 96.62 -176.41 191.66 66.06
2018-09-30 100.55 -180.83 180.52 68.21
2018-06-30 118.99 -146.22 163.42 64.61
2018-03-31 127.93 -131.56 148.05 66.11
2017-12-31 129.30 -128.87 150.34 60.64
2017-09-30 131.90 -112.17 153.06 56.15
2017-06-30 125.77 -124.10 153.93 54.23
2017-03-31 113.80 -123.83 160.07 42.11
2016-12-31 104.60 -110.19 140.44 38.23
2015-12-31 61.76 -59.56 87.86 19.00
2014-12-31 40.96 -74.58 60.93 17.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bonesupport Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bonesupport Holding has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bonesupport Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bonesupport Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bonesupport Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2B4 Health

 How is Bonesupport Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bonesupport Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bonesupport Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bonesupport Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bonesupport Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Bonesupport Holding has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bonesupport Holding Company Filings, last reported 3 months ago.

DB:2B4 Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 278.53 0.00 261.47
2018-09-30 325.02 0.00 313.17
2018-06-30 381.21 0.00 368.36
2018-03-31 416.76 0.00 397.18
2017-12-31 450.79 98.62 533.37
2017-09-30 499.72 91.36 567.64
2017-06-30 464.81 98.79 558.29
2017-03-31 9.10 103.59 103.29
2016-12-31 34.30 109.70 141.50
2015-12-31 20.33 62.89 68.88
2014-12-31 -43.52 66.80 18.39
  • Bonesupport Holding has no debt.
  • Bonesupport Holding currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bonesupport Holding has sufficient cash runway for 1.5 years based on current free cash flow.
  • Bonesupport Holding has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 27.7% each year.
X
Financial health checks
We assess Bonesupport Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bonesupport Holding has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2B4 Dividends

 What is Bonesupport Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bonesupport Holding dividends. Estimated to be 0% next year.
If you bought €2,000 of Bonesupport Holding shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bonesupport Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bonesupport Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2B4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2B4 Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bonesupport Holding has not reported any payouts.
  • Unable to verify if Bonesupport Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bonesupport Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bonesupport Holding has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Bonesupport Holding's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Bonesupport Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bonesupport Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bonesupport Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2B4 Management

 What is the CEO of Bonesupport Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Emil Billbäck
AGE 48
TENURE AS CEO 1.1 years
CEO Bio

Mr. Emil Billbäck has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executive Officer of BONESUPPORT AB. He has over 20 years management experience from the life science industry. Mr. Billbäck serves as Senior Advisor of Essity, following its acquisition of BSN Medical from the Swedish private equity group EQT in 2017. Prior to this, he was a member of the Group Executive Board/Management Committee at BSN Medical, where he held the position of Executive Vice President EMEA and Head of Global Commercial Operations. Mr. Billbäck spent over 13 years in senior management roles at BSN Medical, including Interim President of North America and Group Director Commercial Operations and R&D

CEO Compensation
  • Insufficient data for Emil to compare compensation growth.
  • Insufficient data for Emil to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Bonesupport Holding management team in years:

1.1
Average Tenure
53
Average Age
  • The average tenure for the Bonesupport Holding management team is less than 2 years, this suggests a new team.
Management Team

Johan Olsson

TITLE
Chief Operating Officer
AGE
53

Emil Billbäck

TITLE
Chief Executive Officer
AGE
48
TENURE
1.1 yrs

Håkan Johansson

TITLE
Chief Financial Officer
AGE
55
TENURE
0.3 yrs

Annelie Vikner

TITLE
Executive Vice President Global Marketing & Communications
TENURE
0.1 yrs

Helena Brandt

TITLE
Head of Human Resources
AGE
53
TENURE
1.5 yrs

Vikram Johri

TITLE
GM & Executive VP of International Commercial Operations
AGE
53

Michael Diefenbeck

TITLE
Chief Medical Officer
AGE
44
TENURE
2 yrs

Jerry Chang

TITLE
Executive Vice President of R&D
AGE
59
TENURE
1.6 yrs

Patrick O'Donnell

TITLE
GM & Executive VP of Commercial Operations NA
AGE
53

Linda Butcher

TITLE
Vice President of Training & Events
AGE
55
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Bonesupport Holding board of directors in years:

2.3
Average Tenure
61
Average Age
  • The average tenure for the Bonesupport Holding board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sven Björklund

TITLE
Chairman of the Board
COMPENSATION
SEK375K
AGE
62
TENURE
2.3 yrs

Tone Kvåle

TITLE
Director
COMPENSATION
SEK275K
AGE
49
TENURE
2.3 yrs

Lars Lidgren

TITLE
Director
COMPENSATION
SEK150K
AGE
75
TENURE
9.3 yrs

Björn Odlander

TITLE
Director
COMPENSATION
SEK175K
AGE
60
TENURE
9.3 yrs

Nina Rawal

TITLE
Director
COMPENSATION
SEK220K
AGE
39
TENURE
3.5 yrs

Lennart Johansson

TITLE
Director
COMPENSATION
SEK220K
AGE
63
TENURE
2.3 yrs

Simon Cartmell

TITLE
Director
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Bonesupport Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bonesupport Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2B4 News

Simply Wall St News

2B4 Company Info

Description

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes for the treatment of bone voids Sweden and internationally. The company offers CERAMENT Bone Void Filler used to fill gaps and voids in bone; CERAMENT G, a gentamicin-eluting injectable synthetic bone substitute; and CERAMENT V, a vancomycin-eluting synthetic bone substitute. Its products are used by orthopedic surgeons. The company was founded in 1999 and is headquartered in Lund, Sweden.

Details
Name: Bonesupport Holding AB (publ)
2B4
Exchange: DB
Founded: 1999
SEK109,937,308
51,795,917
Website: http://www.bonesupport.com
Address: Bonesupport Holding AB (publ)
Scheelevagen 19,
Lund,
Skåne County, 223 70,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BONEX Common Shares OMX Nordic Exchange Stockholm SE SEK 21. Jun 2017
DB 2B4 Common Shares Deutsche Boerse AG DE EUR 21. Jun 2017
LSE 0RQO Common Shares London Stock Exchange GB SEK 21. Jun 2017
Number of employees
Current staff
Staff numbers
72
Bonesupport Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:35
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.